Elsevier

Metabolism

Volume 41, Issue 5, May 1992, Pages 487-493
Metabolism

Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of triglyceride-rich lipoproteins☆

https://doi.org/10.1016/0026-0495(92)90206-PGet rights and content

Abstract

We have previously reported decreased production rates of the major apolipoprotein B (apoB)-containing lipoproteins, very-low-density lipoproteins (VLDL), and low-density lipoproteins (LDL) in patients with combined hyperlipidemia (CHL) during treatment with lovastatin. In the present study, we determined the effects of lovastatin therapy on VLDL triglyceride (TG) metabolism. Plasma VLDL turnover was determined in six CHL patients, before and during lovastatin therapy. 3H-triglyceride-glycerol-specific activity data derived from injection of 3H-glycerol were analyzed by compartmental modeling. The effects of lovastatin on VLDL TG metabolism were compared with those previously determined on VLDL apoB metabolism in these subjects. Lovastatin therapy was associated with decreased concentrations of VLDL TG in five of six patients and decreased VLDL apoB concentrations in all six. VLDL TG production rates (PR) decreased in five patients, with the mean for the group decreasing from 14.1 ± 7.1 to 10.3 ± 4.0 mg/kg/h (P < .05). VLDL apoB PR also decreased in five patients, with the mean decreasing from 21.8 ± 20.3 to 12.2 ± 9.0 mg/kg/d (P = .11). Changes in VLDL TG concentrations during lovastatin treatment were correlated with changes in VLDL apoB concentrations (r = .74, P = .09) and in VLDL TG PR (r = .91, P = .01). Changes in VLDL TG PR were also related to changes in VLDL apoB PR (r = .62, P = NS). There were no consistent changes in the fractional catabolic rates of either VLDL TG or VLDL apoB during lovastatin therapy. These findings suggest that, in CHL patients, reductions in VLDL TG concentrations during lovastatin therapy are usually associated with decreased VLDL TG PR, and these effects parallel concomitant reductions in VLDL apoB PR. Taken together with our previous finding of reduced total apoB secretion into plasma during lovastatin treatment, these results support the hypothesis that the overall hypolipidemic effects of lovastatin in patients with CHL are due to decreased assembly and secretion of apoB-containing lipoproteins.

References (44)

  • Y-S Chao et al.

    Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolemia induced by a wheat starch casein diet

    Biochim Biophys Acta

    (1983)
  • JL Dixon et al.

    Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from HepG2 cells by inhibiting early intracellular degradation of apolipoprotein B

    J Biol Chem

    (1991)
  • KM Cianflone et al.

    Regulation of apoB secretion from HepG2 cells: Evidence for a critical role for cholesteryl ester synthesis in the response to fatty acid challenge

    J Lipid Res

    (1990)
  • SM Grundy et al.

    Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man

    J Lipid Res

    (1981)
  • GA Cook et al.

    Feeding of lovastatin to rats increases the activity of the hepatic mitochondrial outer carnitine palmitoyltransferase

    Biochem Biophys Res Commun

    (1988)

  • Cholesterol adult treatment panel report: Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults

    Arch Intern Med

    (1988)
  • JL Goldstein et al.

    The low-density lipoprotein pathway and its relation to atherosclerosis

    Annu Rev Biochem

    (1977)
  • JL Goldstein et al.

    Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

    J Clin Invest

    (1977)
  • G Heiss et al.

    Lipoprotein cholesterol distributions in selected North American populations. The Lipid Research Clinics Program Prevalence Study

    Circulation

    (1980)
  • B Teng et al.

    Metabolic basis of hyperapobetalipoproteinemia: Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia

    J Clin Invest

    (1986)
  • ED Janus et al.

    Kinetic bases of the primary hyperlipidemias: Studies of apolipoprotein B turnover in genetically defined subjects

    Eur J Clin Invest

    (1980)
  • T Langer et al.

    The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia

    J Clin Invest

    (1972)

    • Cited by (0)

    ☆

    Supported by National Institutes of Health-National Heart, Lung, and Blood Institute Grants No. HL 36000, HL 21006, HL 07343, and RR 645.

    View full text
    Copyright © 1992 Published by Elsevier Inc.